[Treatment of prolactinoma with a new dopamine agonist].
Eleven patients (6 men, 5 women, mean age 42 [25-65] years) with prolactinomas were treated for 4-16 months with a new dopamine agonist (CV 205-502), at a daily dose of between 0.075 and 0.45 mg. All patients had previously undergone surgery and/or been treated with bromocriptine or lisuride, but had not tolerated this therapy well, and/or had not shown sufficient suppression of serum prolactin levels. Baseline prolactin levels were between 149 and 4120 ng/ml. During treatment, levels fell significantly in all patients, to between 2.0 and 683 ng/ml, and to within the reference range in five patients. In seven patients, the adenoma size decreased by 10 to greater than 50%. Adverse reactions were less frequent and less marked than with the prior therapy. The new dopamine agonist is an alternative treatment for prolactinomas where other therapies have been unsuccessful.
Svoboda
T
T
2. Medizinische Universitätsklinik und Neurochirurgische Universitätsklinik sowie Ludwig-Boltzmann-Institut für klinische Endokrinologie, Wien.
Luger
A
A
Knosp
E
E
Geyer
G
G
D000328:Adult; D000368:Aged; D000634:Aminoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008090:Lisuride / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
D000634:Aminoquinolines; D015259:Dopamine Agents; D001971:Bromocriptine; C046650:quinagolide; D011388:Prolactin; D008090:Lisuride
Prolactinom-Behandlung mit einem neuen Dopaminagonisten.